BL-918 |
カタログ番号GC39481
One-Click Copy Product Info
|
BL-918 は、EC50 が 24.14 nM の経口活性 UNC-51 様キナーゼ 1 (ULK1) アクチベーターです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2101517-69-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BL-918 is an activator of UNC-51-like kinase 1 (ULK1; EC50=24.14nM). BL-918 can induce cytoprotective autophagy by targeting the ULK complex, while increasing ULK1 phosphorylation at Ser317 and Ser555 and decreasing phosphorylation at Ser757 to activate the autophagy pathway. BL-918 can be used in research related to Parkinson's disease and amyotrophic lateral sclerosis[1-4].
In vitro, BL-918 (0.5–5μM) was used to treat SH-SY5Y cells for 6 hours. BL-918 significantly enhanced cell viability and induced cytoprotective autophagy[5]. BL-918 (20μM) was co-treated with 6-OHDA (50μM) or 1-methyl-4-phenylpyridinium (1mM) in SH-SY5Y cells for 24 hours. BL-918 significantly attenuated neurotoxicity and protected mitochondrial function[6].
In vivo, BL-918 (40 or 80mg/kg; twice daily by oral gavage) was administered to SODG93A mice for 46 weeks. BL-918 dose-dependently extended lifespan and improved motor function[7]. BL-918 (40mg/kg; once daily orally) was used to treat an MPTP (25mg/kg; once daily intraperitoneal injection; days 3–7)-induced Parkinson's disease mouse model for 12 days. BL-918 significantly improved motor function and alleviated the loss of dopaminergic neurons, and these effects were PINK1-dependent[8].
References:
[1] Yang J, Wu Q, Li Y, et al. BL-918 alleviates oxidative stress in rats after subarachnoid hemorrhage by promoting mitophagy through the ULK1/PINK1/Parkin pathway. Free Radic Biol Med. 2024 Nov 1;224:846-861.
[2] Anjum F, Hawsawi N, Almalki AA, et al. Exploring bioactive phytochemicals as ULK1 activators for enhancing cytoprotective autophagy in amyotrophic lateral sclerosis. Front Pharmacol. 2025 Sep 4;16:1661744.
[3] Zhang L, He C, Liu Z, et al. Benfotiamine, a Lipid-Soluble Derivative of Vitamin B1, Ameliorates the Carbohydrate Overload-Induced Mitochondrial Dysfunction in Fish Megalobrama amblycephala by Triggering the ULK1-Mediated Mitophagy. Aquac Nutr. 2025 May 1;2025:7688386.
[4] Gong Y, Deng Z, Wu J, et al. Ferrodoxin 1 (FDX1) drives paclitaxel resistance in ovarian cancer via copper metabolism and ULK1/ATG13-mediated autophagy: overcome by pH/ROS-responsive PPD/PDP@si-FDX1 nanomicelles. J Exp Clin Cancer Res. 2026 Apr 23;45(1):104.
[5] Ouyang L, Zhang L, Zhang S, et al. Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment. J Med Chem. 2018 Apr 12;61(7):2776-2792.
[6] Lee C, Kim DY, Kim SM, et al. HUWE1 regulates mitophagy to protect dopaminergic neurons from 6-OHDA- and MPP⁺-induced neurotoxicity. Cell Biol Toxicol. 2026 Feb 5;42(1):34.
[7] Liu W, Zhu SO, Guo YL, et al. BL-918, a small-molecule activator of ULK1, induces cytoprotective autophagy for amyotrophic lateral sclerosis therapy. Acta Pharmacol Sin. 2023 Mar;44(3):524-537.
[8] Wang Y, Luo S, Su H, et al. BL-918 activates PINK1/Parkin signaling pathway to ameliorate the progression of Parkinson's disease. J Biol Chem. 2024 Aug;300(8):107543.
| Cell experiment [1]: | |
Cell lines | SH-SY5Y cells (human neuroblastoma cell line) |
Preparation Method | SH-SY5Y cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. SH-SY5Y cells were treated with BL-918 (20μM) together with 6-hydroxydopamine (6-OHDA; 50μM) or 1-methyl-4-phenylpyridinium (MPP+; 1mM) for 24 hours. |
Reaction Conditions | 20μM, 24h |
Applications | BL-918 treatment significantly attenuated 6-OHDA- and MPP+-induced neurotoxicity and protected mitochondrial function. BL-918 promotes AMBRA1 recruitment, facilitated HUWE1-mediated mitophagy in SH-SY5Y cells. |
| Animal experiment [2]: | |
Animal models | WT C57BL/6 mice and Pink1-deficient (Pink1-/-) mice |
Preparation Method | Mice treated with 40mg/kg BL-918 by oral gavage once daily from day 1–12 and intraperitoneally injected with 25mg/kg MPTP once daily from day 3–7. Behavioral tests (rotarod and pole test) were performed. Immunoblotting and immunofluorescence were used to detect tyrosine hydroxylase (TH) and dopamine transporter (DAT) in substantia nigra and striatum. |
Dosage form | 40mg/kg; oral gavage; once daily for 12 days |
Applications | BL-918 treatment restored MPTP-induced impairment of motor function in WT mice but not in Pink1-/- mice. BL-918 mitigated the reduction of TH protein level in substantia nigra and alleviated the loss of TH-positive and DAT-positive dopaminergic neurons in substantia nigra, as well as the reduction of TH-positive fiber density in striatum, in a PINK1-dependent manner. |
References: | |
| Cas No. | 2101517-69-3 | SDF | |
| Canonical SMILES | O=C(NC1=CC=C(F)C=C1F)[C@H](NC(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=S)C3=CC=CC=C3 | ||
| Formula | C23H15F8N3OS | M.Wt | 533.44 |
| 溶解度 | DMSO: ≥ 250 mg/mL (468.66 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8746 mL | 9.3731 mL | 18.7463 mL |
| 5 mM | 374.9 μL | 1.8746 mL | 3.7493 mL |
| 10 mM | 187.5 μL | 937.3 μL | 1.8746 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)